A Randomized, Controlled, Open-Label, Multicenter, Phase 2 Study of Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine as First-Line Treatment in Patients With Recurrent/Metastatic Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
Price : $35 *
At a glance
- Drugs Nimotuzumab (Primary) ; Capecitabine; Docetaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Jun 2015 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as per ClinicalTrials.gov.
- 03 Jun 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov..